{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:18:08Z","timestamp":1785251888352,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Assistance Publique-H\u00f4pitaux de Paris"},{"name":"MD-PhD program of INSERM"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV2 infection has a poor prognosis in patients affected of idiopathic pulmonary fibrosis (IPF). Autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) are found in the blood of at least 15% of patients with life-threatening COVID-19 pneumonia. Because of the elevated prevalence of some auto-Abs in IPF patients, we hypothesize that the prevalence of auto-Abs neutralizing type I IFNs might be increased in the IPF population and then explained specific poor outcome after COVID-19. We screened the plasma of 247 consecutive IPF patients for the presence of auto-Abs neutralizing type I IFNs. Three patients displayed auto-Abs neutralizing type I IFNs. Among them, the only patient with documented SARS-CoV-2 infection experienced life threatening COVID-19 pneumonia. The prevalence of auto-Abs neutralizing type I IFNs in this cohort of IPF patients was not significantly different from the one of the general population. Overall, this study did not suggest any association between auto-Abs neutralizing type I IFNs and IPF.<\/jats:p>","DOI":"10.1186\/s12931-023-02396-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:55:35Z","timestamp":1679864135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Quentin","family":"Philippot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Puel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Cobat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Laou\u00e9nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Tardivon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Borie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"129","key":"2396_CR1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1183\/09059180.00000713","volume":"22","author":"PL Molyneaux","year":"2013","unstructured":"Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(129):376\u201381.","journal-title":"Eur Respir Rev"},{"key":"2396_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.815924","volume":"9","author":"Y Goto","year":"2022","unstructured":"Goto Y, Sakamoto K, Fukihara J, Suzuki A, Omote N, Ando A, et al. COVID-19-triggered acute exacerbation of IPF, an underdiagnosed clinical entity with two-peaked respiratory failure: a case report and literature review. Front Med. 2022;9: 815924.","journal-title":"Front Med"},{"issue":"10","key":"2396_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244472","volume":"14","author":"N Earl","year":"2021","unstructured":"Earl N, Schoeneberg D, Davidson PD. Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection. BMJ Case Rep. 2021;14(10): e244472.","journal-title":"BMJ Case Rep"},{"issue":"12","key":"2396_CR4","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1164\/rccm.201010-1752OC","volume":"183","author":"SC Wootton","year":"2011","unstructured":"Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698\u2013702.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2396_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1164\/rccm.202007-2638LE","volume":"203","author":"L Gallay","year":"2021","unstructured":"Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med. 2021;203(2):245\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"62","key":"2396_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4340","volume":"6","author":"P Bastard","year":"2021","unstructured":"Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62): eabl4340.","journal-title":"Sci Immunol"},{"issue":"21","key":"2396_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200413119","volume":"119","author":"J Manry","year":"2022","unstructured":"Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci USA. 2022;119(21): e2200413119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rmed.2017.12.011","volume":"135","author":"G Beltramo","year":"2018","unstructured":"Beltramo G, Thabut G, Peron N, Nicaise P, Cazes A, Debray MP, et al. Anti-parietal cell autoimmunity is associated with an accelerated decline of lung function in IPF patients. Respir Med. 2018;135:15\u201321.","journal-title":"Respir Med"},{"issue":"5","key":"2396_CR9","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"2396_CR10","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409\u201319.","journal-title":"Stat Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02396-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:56:31Z","timestamp":1679864191000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02396-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02396-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the \u201cComit\u00e9 de Protection des Personnes Ile de France 1\u201d (n\u00b0 0911932) and was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained for all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Q.P. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead. J.-L.C. is an inventor on patent application PCT\/US2021\/042741, filed July 22, 2021, submitted by The Rockefeller University that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including Covid-19 and vaccine-associated diseases. B.C. received grants from BMS, Boehringer Ingelheim and Roche, consulting fees from apellis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, BMS, Roche, Sanofi, Novartis, Astra Zeneca and Chiesi, and receipt of equipment, materials, drugs, medical writing, gifts or other services from Translate Bio. R.B. received grants from Roche, Boehringer Ingelheim and Sanofi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Boehringer Ingelheim and Sanofi, and participated on a Data Safety Monitoring Board or Advisory Board for SAvara.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}